Article

Haplotype selection as an adaptive mechanism in the protozoan pathogen Leishmania donovani

  • Nature Ecology & Evolutionvolume 1pages19611969 (2017)
  • doi:10.1038/s41559-017-0361-x
  • Download Citation
Received:
Accepted:
Published online:

Abstract

The parasite Leishmania  donovani causes a fatal disease termed visceral leishmaniasis. The process through which the parasite adapts to environmental change remains largely unknown. Here we show that aneuploidy is integral for parasite adaptation and that karyotypic fluctuations allow for selection of beneficial haplotypes, which impact transcriptomic output and correlate with phenotypic variations in proliferation and infectivity. To avoid loss of diversity following karyotype and haplotype selection, L. donovani utilizes two mechanisms: polyclonal selection of beneficial haplotypes to create coexisting subpopulations that preserve the original diversity, and generation of new diversity as aneuploidy-prone chromosomes tolerate higher mutation rates. Our results reveal high aneuploidy turnover and haplotype selection as a unique evolutionary adaptation mechanism that L. donovani uses to preserve genetic diversity under strong selection. This unexplored process may function in other human diseases, including fungal infection and cancer, and stimulate innovative treatment options.

  • Subscribe to Nature Ecology & Evolution for full access:

    $99

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Pallen, M. J. & Wren, B. W. Bacterial pathogenomics. Nature 449, 835–842 (2007).

  2. 2.

    Torres, E. M. et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 317, 916–924 (2007).

  3. 3.

    Pavelka, N. et al. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature 468, 321–325 (2010).

  4. 4.

    Pavelka, N., Rancati, G. & Li, R. Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer. Curr. Opin. Cell Biol. 22, 809–815 (2010).

  5. 5.

    Selmecki, A. M., Dulmage, K., Cowen, L. E., Anderson, J. B. & Berman, J. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet. 5, e1000705 (2009).

  6. 6.

    Sabeti, P. C. et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 419, 832–837 (2002).

  7. 7.

    Staaf, J. et al. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int. J. Cancer 132, 2020–2031 (2013).

  8. 8.

    Scheinfeldt, L. B. & Tishkoff, S. A. Recent human adaptation: genomic approaches, interpretation and insights. Nat. Rev. Genet. 14, 692–702 (2013).

  9. 9.

    Gao, R. et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat. Genet. 48, 1119–1130 (2016).

  10. 10.

    Sterkers, Y., Crobu, L., Lachaud, L., Pagès, M. & Bastien, P. Parasexuality and mosaic aneuploidy in Leishmania: alternative genetics. Trends Parasitol. 30, 429–435 (2014).

  11. 11.

    Imamura, H. et al. Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. Elife 5, e12613 (2016).

  12. 12.

    Alvar, J. et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7, e35671 (2012).

  13. 13.

    Zilberstein, D. & Shapira, M. The role of pH and temperature in the development of Leishmania parasites. Annu. Rev. Microbiol. 48, 449–470 (1994).

  14. 14.

    Leprohon, P., Fernandez-Prada, C., Gazanion, É., Monte-Neto, R. & Ouellette, M. Drug resistance analysis by next generation sequencing in Leishmania. Int. J. Parasitol. Drugs Drug Resist. 5, 26–35 (2015).

  15. 15.

    Downing, T. et al. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 21, 2143–2156 (2011).

  16. 16.

    Dujardin, J.-C., Mannaert, A., Durrant, C. & Cotton, J. A. Mosaic aneuploidy in Leishmania: the perspective of whole genome sequencing. Trends Parasitol. 30, 554–555 (2014).

  17. 17.

    Rogers, M. B. et al. Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res. 21, 2129–2142 (2011).

  18. 18.

    Sterkers, Y., Lachaud, L., Crobu, L., Bastien, P. & Pagès, M. FISH analysis reveals aneuploidy and continual generation of chromosomal mosaicism in Leishmania major. Cell. Microbiol. 13, 274–283 (2011).

  19. 19.

    Dumetz, F. et al. Modulation of aneuploidy in Leishmania donovani during adaptation to different in vitro and in vivo environments and its impact on gene expression. MBio 8, e00599-17 (2017).

  20. 20.

    Legrand, M. et al. Haplotype mapping of a diploid non-meiotic organism using existing and induced aneuploidies. PLoS Genet. 4, e1 (2008).

  21. 21.

    Yona, A. H. et al. Chromosomal duplication is a transient evolutionary solution to stress. Proc. Natl Acad. Sci. USA 109, 21010–21015 (2012).

  22. 22.

    Sterkers, Y. et al. Novel insights into genome plasticity in eukaryotes: mosaic aneuploidy in Leishmania. Mol. Microbiol. 86, 15–23 (2012).

  23. 23.

    Rougeron, V., De Meeûs, T., Kako Ouraga, S., Hide, M. & Bañuls, A.-L. ‘Everything you always wanted to know about sex (but were afraid to ask)’ in Leishmania after two decades of laboratory and field analyses. PLoS Pathog. 6, e1001004 (2010).

  24. 24.

    Lande, R. Natural selection and random genetic drift in phenotypic evolution. Evolution 30, 314–334 (1976).

  25. 25.

    Lynch, M. & Conery, J. S. The evolutionary fate and consequences of duplicate genes. Science 290, 1151–1155 (2000).

  26. 26.

    Victoir, K. & Dujardin, J.-C. How to succeed in parasitic life without sex? Asking Leishmania. Trends Parasitol. 18, 81–85 (2002).

  27. 27.

    Bastien, P., Blaineau, C. & Pages, M. Leishmania: sex, lies and karyotype. Parasitol. Today 8, 174–177 (1992).

  28. 28.

    Dujardin, J.-C. et al. Clonal propagation and the fast generation of karyotype diversity: an in vitro Leishmania model. Parasitology 134, 33–39 (2007).

  29. 29.

    Gazanion, É., Fernández-Prada, C., Papadopoulou, B., Leprohon, P. & Ouellette, M. Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania. Proc. Natl Acad. Sci. USA 113, E3012–E3021 (2016).

  30. 30.

    Pescher, P., Blisnick, T., Bastin, P. & Späth, G. F. Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation. Cell. Microbiol. 13, 978–991 (2011).

  31. 31.

    Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

  32. 32.

    Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

  33. 33.

    McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).

  34. 34.

    Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).

  35. 35.

    Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621–628 (2008).

Download references

Acknowledgements

Work on samples from the Indian subcontinent was supported by the European Union 7th Framework Programme (EU FP7) (Kaladrug-R, contract 222895), the Belgian Science Policy Office (TRIT, P7/41), the Department of Economy, Science and Innovation in Flanders (ITM-SOFIB) and the Flemish Fund for Scientific Research (G.0.B81.12). We thank Life Science Editors for editing assistance. This study recieved funding from Plan Nacional (BFU2011-28575 to C.N., P.P.B. and D.K.), Center for Genomic Regulation (CRG), Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013–2017’ (SEV-2012–0208), a grant from the Institut Pasteur International Department strategic fund to the LeiSHield consortium (P.P.B., P.P, C.N., G.F.S., G.B. and Y.S.), Agence Nationale de la Recherche (ANR) within the framework of the 'Investissements d’avenir' programme (ANR-11-LABX-0024-01 “PARAFRAP”) (V.C., M.P. and Y.S.), the EU FP7 (Kaladrug-R, contract 222895), the Belgian Science Policy Office (TRIT, P7/41), the Department of Economy, Science and Innovation in Flanders (ITM-SOFIB) and the Flemish Fund for Scientific Research (G.0.B81.12) (J.C.D., F.D., H.I. and M.D.).

Author information

Author notes

  1. These authors contributed equally to this work: Pablo Prieto Barja, Pascale Pescher.

Affiliations

  1. Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, 08002, Barcelona, Spain

    • Pablo Prieto Barja
    • , Darek Kedra
    • , Heinz Himmelbauer
    •  & Cedric Notredame
  2. Universitat Pompeu Fabra (UPF), 08002, Barcelona, Spain

    • Pablo Prieto Barja
    •  & Cedric Notredame
  3. Institut Pasteur, INSERM U1201, Unité de Parasitologie Moléculaire et Signalisation, 75015, Paris, France

    • Pascale Pescher
    •  & Gerald Frank Späth
  4. HUB de Bioinformatique et Biostatistiques, Centre de Bioinformatique, Biostatistique et Biologie Intégrative (C3BI), Institut Pasteur, 75015, Paris, France

    • Giovanni Bussotti
  5. Institute of Tropical Medicine, Molecular Parasitology Unit, B-2000, Antwerp, Belgium

    • Franck Dumetz
    • , Hideo Imamura
    • , Malgorzata Domagalska
    •  & Jean-Claude Dujardin
  6. University Montpellier, Faculty of Medicine, Laboratory of Parasitology–Mycology, CNRS 5290, IRD 224, University Montpellier (UMR ‘MiVEGEC’) and Centre Hospitalier Universitaire, 34295, Montpellier cedex 5, France

    • Victor Chaumeau
    • , Michel Pages
    •  & Yvon Sterkers
  7. Institute of Biotechnology, 1190, Vienna, Austria

    • Heinz Himmelbauer
  8. Department of Biomedical Sciences, University of Antwerp, B-2610, Antwerp, Belgium

    • Jean-Claude Dujardin

Authors

  1. Search for Pablo Prieto Barja in:

  2. Search for Pascale Pescher in:

  3. Search for Giovanni Bussotti in:

  4. Search for Franck Dumetz in:

  5. Search for Hideo Imamura in:

  6. Search for Darek Kedra in:

  7. Search for Malgorzata Domagalska in:

  8. Search for Victor Chaumeau in:

  9. Search for Heinz Himmelbauer in:

  10. Search for Michel Pages in:

  11. Search for Yvon Sterkers in:

  12. Search for Jean-Claude Dujardin in:

  13. Search for Cedric Notredame in:

  14. Search for Gerald Frank Späth in:

Contributions

P.P.B., P.P, C.N. and G.F.S worked on all aspects of work, contributed to the design of the project and wrote the article. G.B contributed to in silico analysis. F.D. and M.D. managed the hamster infection experiment with field isolates. H.I., M.D. and J.-C.D. contributed to the field isolates analyses and revised the paper. D.K. helped analyse the sequencing data. H.H. was responsible for the genomic sequencing of the in vitro clones. V.C., M.P. and Y.S. contributed the DNA-FISH analysis.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Cedric Notredame or Gerald Frank Späth.

Electronic supplementary material

  1. Supplementary Information

    Supplementary Figures 1–12, Supplementary Tables 1–2.

  2. Life Sciences Reporting Summary